Medicines UK

What Medicines UK does

Medicines UK (legally British Generic Manufacturers Association Ltd) is the UK trade association for manufacturers and suppliers of off-patent medicines, including generics, biosimilars, and value-added medicines. The association represents 45 pharmaceutical companies that collectively supply approximately nine out of ten prescription medicines used by the NHS and account for around 85% of the UK off-patent market by volume, with off-patent competition generating more than £20 billion in annual NHS savings and over 1 billion items prescribed generically each year in England and Wales.

Medicines UK operates as a policy advocacy and stakeholder coordination body rather than a product company. Its core 'products' are industry initiatives such as Project Revive (a collaboration with NHS England and the MHRA to revive dormant MHRA-approved licenses for ~400 resilience-priority medicines), educational webinars on biosimilar regulatory pathways, comparative research reports, and an annual conference. The organization maintains a Quality Forum with the MHRA three times a year and provides members with prioritized regulatory advice (committed within four weeks under Project Revive).

The business model is membership-driven. Revenue is generated through subscription/recurring membership fees from 45 pharmaceutical companies, with size undetermined but consistent with a small operating budget given ~10 employees. The association does not sell products or services to end customers; its direct customers are member companies, while the NHS functions as the ultimate downstream beneficiary of the sector's supply. The GTM motion is sales-led relationship management with government, NHS England, MHRA, NICE, and parliamentary stakeholders.

Name

Medicines UK

Legal name

British Generic Manufacturers Association Ltd

Website

https://medicinesuk.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Medicines UK is the UK trade association for manufacturers and suppliers of generic, biosimilar, and value-added medicines, representing 45 companies that supply approximately 85% of NHS prescriptions and deliver more than £20 billion in annual NHS savings.

Ownership category

akta.pro rank

Product category

Pharmaceutical trade association

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Tender & Government Supply Markets (HLAIABAM), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical trade association
• Generic medicines advocacy
• Biosimilar industry representation
• Off-patent medicines policy
• NHS supply chain

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Membership fees: Medicines UK operates as a trade association representing the off-patent pharmaceutical sector. Revenue is generated through membership fees from 45 pharmaceutical companies that specialize in manufacturing and supplying the NHS with off-patent generic and biosimilar medicines. The association does not sell products but provides value through advocacy, policy influence, and industry representation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Medicines UK is a UK trade association representing 45 pharmaceutical manufacturers and suppliers of off-patent generic, biosimilar, and value-added medicines. The association provides industry advocacy, regulatory engagement with the MHRA, NHS England, and NICE, policy development, and member services including conferences and educational events. Its core activity is shaping the policy and commercial environment for the off-patent pharmaceutical sector that supplies approximately 85% of NHS prescriptions.

Product overview

Medicines UK is a trade body representing manufacturers and suppliers of generic, biosimilar, and value-added medicines. The organization does not offer traditional software products but provides an information resource platform, industry initiatives (such as Project Revive), educational webinars on biosimilar regulatory pathways, and research reports on biosimilar markets. The website serves as the primary channel for industry news, policy advocacy, and member engagement.

Differentiator

Problem solved

Functional benefit

Products and services

• Project Revive A collaborative initiative for member companies and NHS partners to revive dormant MHRA-approved medicine licences to address critical medicines shortages in the UK. The pilot identifies near-400 products as resilience priorities or single/no-supplier risks, with prioritised MHRA regulatory support and NHS purchasing arrangements.
• Medicines UK Trade Association Membership Membership of the UK off-patent pharmaceutical trade association for manufacturers and suppliers of generic, biosimilar, and value-added medicines. Members receive industry advocacy, policy representation, regulatory engagement with MHRA/NHS England/NICE, and participation in working groups and conferences.

Quantifiable outcome

• £20 billion in annual savings to NHS healthcare budgets
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• NHS EnglandcoreStrategic or Co-development Partner · 5 February 2026Project Revive is an innovative collaboration between NHS England, the MHRA and Medicines UK. The initiative encourages manufacturers to relaunch dormant MHRA-approved licences through a dedicated regulatory pathway and NHS purchasing arrangements. A list of nearly 400 products has been identified by the NHS for the pilot programme where the NHS considers them a resilience priority, or there is only one or no suppliers.
• MHRA (Medicines and Healthcare products Regulatory Agency)coreStrategic or Co-development Partner · 5 February 2026The MHRA is the UK medicines regulator and partner in Project Revive. The agency provides regulatory advice within four weeks of request and ensures timely assessment of any changes needed to bring unmarketed medicines back into active use. The MHRA also collaborates with Medicines UK through a Quality Forum that meets three times a year.
• NICE (National Institute for Health and Care Excellence)coreStrategic or Co-development PartnerMedicines UK liaises closely with NICE on initiatives which drive uptake and promote access to affordable medicines.
• Patient GroupsminorOthersMedicines UK works with patient groups, think tanks, industry bodies, academia and the media to represent the interests of the off-patent sector.
• International Regulatory BodiesminorOthersMedicines UK works closely with representative and relevant international bodies and organisations, liaising on issues such as regulation, IP, trade, manufacturing and supply. As the UK broadens its free trade agreements with key international partners, engagement on medicines supply is important for national security.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• European Federation of Pharmaceutical Industries and Associations (EFPIA): The European trade body representing the research-based pharmaceutical industry. Comparable as a pharma policy advocacy association engaging EU regulators and member-state bodies, though representing originator rather than off-patent manufacturers.
• BioIndustry Association (BIA): The UK trade association for the life sciences and biotech sector. Comparable as a UK life-sciences industry body engaging with MHRA, NICE and government, though focused on innovative biotech rather than off-patent medicines.
• Association of the British Pharmaceutical Industry (ABPI): The UK trade body for the broader pharmaceutical industry, including branded originator companies. Comparable as a UK pharma trade association engaged with NHS England, MHRA and NICE, but representing the innovator side rather than the off-patent sector.
• International Generic and Biosimilar Medicines Association (IGBA): The international federation of generic and biosimilar medicines associations. Directly comparable to Medicines UK at the global level, coordinating policy and advocacy across national off-patent industry bodies.

Direct peers

• Medicines for Europe: The European trade association representing generic, biosimilar and value-added medicines manufacturers. Directly comparable to Medicines UK as the pan-European counterpart advocating for off-patent competition and member companies.
• Association for Accessible Medicines (AAM): The US trade association for generic and biosimilar manufacturers (formerly GPhA). Closely comparable as a national off-patent industry body focused on policy advocacy, member representation and market access for generics and biosimilars.

Regional players

• Japan Generic Medicines Association: Japan's national trade association for generic medicines manufacturers. Comparable in mandate (promoting generic uptake, policy advocacy, regulatory engagement), though operating in the distinct Japanese regulatory and reimbursement environment.
• Canadian Generic Pharmaceutical Association (CGPA): Canada's national trade association representing generic pharmaceutical manufacturers. Comparable in mandate (generic market access, pricing policy, member advocacy) though operating within a Canadian regulatory and reimbursement system.
• ProGenerika: The German trade association for generic medicines manufacturers. Comparable as a national generic industry body with similar policy, pricing and supply-chain advocacy mandates, but operating in a different EU member-state market.

Emerging players

• British Biosimilars Association: A sub-brand within Medicines UK itself focused specifically on the UK biosimilars sector. Highly comparable given shared governance and resources, but with a narrower biosimilars-only mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/medicinesuk

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines UK